Cancer‐specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989‐2005)

Abstract

Most patients with localized RCC do well with surgery alone, but effective adjuvant therapy is needed for patients identified as at high risk for recurrence. For advanced disease, newer targeted and potentially less toxic treatments should be at least as effective as those achieved with aggressive surgical resection and immunotherapy.